Home
CAPR
CAPR News

Latest Capricor Therapeutics Inc. (CAPR) News on October 8, 2025

MT Newswires

a month ago

Capricor Therapeutics Files $300 Million Mixed Shelf

Capricor refutes FDA’s DMD deramiocel rejection in public statement

Pharmaceutical Technology

a month ago

Capricor refutes FDA’s DMD deramiocel rejection in public statement

MT Newswires

a month ago

Capricor Posts Response to FDA Complete Response Letter for Deramiocel

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

GlobeNewswire

a month ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) largest shareholders are retail investors with 58% ownership, institutions own 30%

Simply Wall St.

a month ago

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) largest shareholders are retail investors with 58% ownership, institutions own 30%

Capricor Therapeutics Hammered On A Surprise FDA Rejection

Investor's Business Daily

3 months ago

Capricor Therapeutics Hammered On A Surprise FDA Rejection

MT Newswires

3 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

3 months ago

Sector Update: Health Care Stocks Slide Friday Afternoon

MT Newswires

3 months ago

Sector Update: Health Care Stocks Decline Pre-Bell Friday

MT Newswires

3 months ago

Tariff Situation Weighs on Investor Sentiment, Driving Premarket Losses for US Equity Futures

MT Newswires

3 months ago

Sector Update: Health Care

MT Newswires

3 months ago

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday After Surprise Tariff Hikes

MT Newswires

3 months ago

Top Premarket Decliners

US High Growth Tech Stocks with Promising Potential

Simply Wall St.

3 months ago

US High Growth Tech Stocks with Promising Potential

General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls

The Fly

3 months ago

General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls

MT Newswires

3 months ago

B. Riley Initiates Coverage on Capricor Therapeutics With Buy Rating, $21 Price Target

No Ad Comm ‘not necessarily positive’ for Capricor, says Roth Capital

TipRanks

3 months ago

No Ad Comm ‘not necessarily positive’ for Capricor, says Roth Capital

Capricor’s deramiocel moves ahead without AdCom, says H.C. Wainwright

TipRanks

3 months ago

Capricor’s deramiocel moves ahead without AdCom, says H.C. Wainwright

MT Newswires

3 months ago

Capricor Says FDA Advisory Committee Review Not Required for Deramiocel Application

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

GlobeNewswire

3 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

MT Newswires

4 months ago

Oppenheimer Lowers Capricor Therapeutics Price Target to $22 From $43, Maintains Outperform Rating

Capricor Therapeutics announces four-year data from HOPE-2 OLE study

TipRanks

4 months ago

Capricor Therapeutics announces four-year data from HOPE-2 OLE study

MT Newswires

4 months ago

Capricor Reports Slower Disease Progression in 4-Year Duchenne Study

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

GlobeNewswire

4 months ago

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

MT Newswires

4 months ago

Capricor Therapeutics' Deramiocel Wins FDA Orphan Drug Designation for Becker Muscular Dystrophy

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

GlobeNewswire

4 months ago

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

Capricor says FDA inspection brought Form 483 with several observations

TipRanks

4 months ago

Capricor says FDA inspection brought Form 483 with several observations

MT Newswires

4 months ago

Capricor Therapeutics' Duchenne Therapy Facility Inspection Completed by FDA

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

GlobeNewswire

4 months ago

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.

5 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Capricor Therapeutics, Inc.’s (CAPR): Analysts See 489% Upside Potential

Insider Monkey

5 months ago

Capricor Therapeutics, Inc.’s (CAPR): Analysts See 489% Upside Potential

MT Newswires

5 months ago

Roth Capital Initiates Coverage on Capricor Therapeutics With Buy Rating

Analysts Are Upgrading Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Its Latest Results

Simply Wall St.

5 months ago

Analysts Are Upgrading Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Its Latest Results

Capricor Therapeutics First Quarter 2025 Earnings: US$0.53 loss per share (vs US$0.31 loss in 1Q 2024)

Simply Wall St.

5 months ago

Capricor Therapeutics First Quarter 2025 Earnings: US$0.53 loss per share (vs US$0.31 loss in 1Q 2024)

Capricor Therapeutics Inc (CAPR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

GuruFocus.com

5 months ago

Capricor Therapeutics Inc (CAPR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Associated Press Finance

5 months ago

Capricor: Q1 Earnings Snapshot

Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire

5 months ago

Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

GlobeNewswire

5 months ago

Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

What To Expect From Capricor Therapeutics Inc (CAPR) Q1 2025 Earnings

GuruFocus.com

5 months ago

What To Expect From Capricor Therapeutics Inc (CAPR) Q1 2025 Earnings

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

5 months ago

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

GlobeNewswire

5 months ago

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

MT Newswires

5 months ago

Sector Update: Health Care Stocks Lower Monday Afternoon

MT Newswires

5 months ago

Capricor Therapeutics Shares Fall as FDA Plans Panel Review for Duchenne Treatment

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

GlobeNewswire

5 months ago

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ...

GuruFocus.com

6 months ago

Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ...

When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable?

Simply Wall St.

6 months ago

When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable?

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

GlobeNewswire

6 months ago

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

High Growth Tech Stocks In The US Market With Promising Potential

Simply Wall St.

6 months ago

High Growth Tech Stocks In The US Market With Promising Potential

Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

7 months ago

Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings

Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

7 months ago

Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations

Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy?

Insider Monkey

7 months ago

Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy?

Thomson Reuters StreetEvents

7 months ago

Q4 2024 Capricor Therapeutics Inc Earnings Call

Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates

Zacks

7 months ago

Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

7 months ago

Capricor Therapeutics Q4 Loss Widens, Revenue Decreases

Associated Press Finance

7 months ago

Capricor: Q4 Earnings Snapshot

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire

7 months ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership

Simply Wall St.

7 months ago

While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership

Capricor Therapeutics announces long-term data from HOPE-2 OLE study

TipRanks

7 months ago

Capricor Therapeutics announces long-term data from HOPE-2 OLE study

MT Newswires

7 months ago

Capricor Therapeutics Says 3-Year Data Show Deramiocel Slows Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire

7 months ago

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

GlobeNewswire

7 months ago

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

MT Newswires

7 months ago

Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

PR Newswire

7 months ago

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

GlobeNewswire

7 months ago

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory

Insider Monkey

7 months ago

Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition

Benzinga

7 months ago

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition

MT Newswires

7 months ago

Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

GlobeNewswire

7 months ago

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

Is Capricor Therapeutics, Inc. (CAPR) the Best Small-Cap Growth Stock to Buy Now?

Insider Monkey

7 months ago

Is Capricor Therapeutics, Inc. (CAPR) the Best Small-Cap Growth Stock to Buy Now?

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

8 months ago

High Growth Tech Stocks In The United States To Watch

Capricor Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

8 months ago

Capricor Therapeutics to Participate in Upcoming Investor Conferences

Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?

Zacks

8 months ago

Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?

Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone

Simply Wall St.

9 months ago

Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone

Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade

Zacks

9 months ago

Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Zacks

9 months ago

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

MT Newswires

9 months ago

Capricor Completes BLA Submission for Deramiocel to Treat DMD Cardiomyopathy

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire

9 months ago

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

High Growth Tech Stocks To Watch In December 2024

Simply Wall St.

10 months ago

High Growth Tech Stocks To Watch In December 2024

Capricor Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

10 months ago

Capricor Therapeutics to Present at Upcoming Investor Conferences

MT Newswires

a year ago

Capricor Gets Orphan Drug, Advanced Therapy Medicinal Product Designations for Deramiocel in Europe

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

GlobeNewswire

a year ago

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

MT Newswires

a year ago

JonesTrading Initiates Capricor Therapeutics at Buy Rating With $40 Price Target

Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?

Insider Monkey

a year ago

Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?

Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Thomson Reuters StreetEvents

a year ago

Q3 2024 Capricor Therapeutics Inc Earnings Call

Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates

Zacks

a year ago

Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates

MT Newswires

a year ago

Capricor Therapeutics Q3 Net Loss Widens, Revenue Declines From Year-Ago Levels

Associated Press Finance

a year ago

Capricor: Q3 Earnings Snapshot

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

GlobeNewswire

a year ago

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?

Zacks

a year ago

Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?

Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates

Zacks

a year ago

Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates

Verano Holdings Corp. (VRNOF) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a year ago

Verano Holdings Corp. (VRNOF) Expected to Beat Earnings Estimates: Should You Buy?

Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline

Zacks

a year ago

Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

GlobeNewswire

a year ago

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

High Growth Tech Stocks to Watch in October 2024

Simply Wall St.

a year ago

High Growth Tech Stocks to Watch in October 2024

MT Newswires

a year ago

Piper Sandler Initiates Capricor Therapeutics at Overweight With $35 Price Target

MT Newswires

a year ago

Capricor Therapeutics Closes Underwritten Public Offering

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

a year ago

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

MT Newswires

a year ago

Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday

Share on Social Networks: